Cancer treatment and survivorship statistics, CA Cancer J Clin, vol.2012, issue.624, pp.220-241, 2012. ,
La situation du cancer en France en 2010 Collection Rapports & synthèses, ouvrage collectif édité par l'INCa, Boulogne-Billancourt, novembre 2010. [INCa. The situation in France in 2010. Reports and summaries, 2010. ,
Melanoma incidence and mortality in Europe: new estimates, persistent disparities, British Journal of Dermatology, vol.46, issue.5, pp.1124-1130 ,
DOI : 10.1111/j.1365-2133.2012.11125.x
Melanoma biology and new targeted therapy, Nature, vol.98, issue.7130, pp.851-857, 2007. ,
DOI : 10.1038/nature05661
Mutations of the BRAF gene in human cancer, Nature, vol.7, issue.6892, pp.417-949, 2002. ,
DOI : 10.1006/geno.2000.6354
High frequency of BRAF mutations in nevi, Nature Genetics, vol.33, issue.1, pp.19-20, 2003. ,
DOI : 10.1038/nm0798-844
Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis, British Journal of Dermatology, vol.158, issue.4, pp.776-784, 2011. ,
DOI : 10.1111/j.1365-2133.2010.10185.x
in Metastatic Melanoma, Journal of Clinical Oncology, vol.29, issue.10, pp.1239-1246, 2011. ,
DOI : 10.1200/JCO.2010.32.4327
Tumor homogeneity between primary and metastatic sites for BRAF status in metastatic melanoma determined by immunohistochemical and molecular testing. PLoS One, p.23976959, 2013. ,
Is a Single BRAF Wild-Type Test Sufficient to Exclude Melanoma Patients from Vemurafenib Therapy?, Journal of Investigative Dermatology, vol.134, issue.5, pp.1468-1470 ,
DOI : 10.1038/jid.2013.378
Distinct Sets of Genetic Alterations in Melanoma, New England Journal of Medicine, vol.353, issue.20, pp.2135-2147, 2005. ,
DOI : 10.1056/NEJMoa050092
The MAPK pathway in melanoma, Current Opinion in Oncology, vol.20, issue.2, pp.183-189, 2008. ,
DOI : 10.1097/CCO.0b013e3282f5271c
Vemurafenib: The road to personalized medicine in melanoma, Drugs of Today, vol.48, issue.2, pp.109-118, 2012. ,
DOI : 10.1358/dot.2012.48.2.1745274
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma, New England Journal of Medicine, vol.363, issue.9, pp.809-819, 1002011. ,
DOI : 10.1056/NEJMoa1002011
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation, New England Journal of Medicine, vol.364, issue.26, pp.2507-2516, 1103782. ,
DOI : 10.1056/NEJMoa1103782
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity, Proceedings of the National Academy of Sciences, vol.105, issue.8, pp.3041-3046, 2008. ,
DOI : 10.1073/pnas.0711741105
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma, New England Journal of Medicine, vol.367, issue.2, pp.107-114, 1203421. ,
DOI : 10.1056/NEJMoa1203421
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial, The Lancet, vol.380, issue.9839, pp.358-365 ,
DOI : 10.1016/S0140-6736(12)60868-X
Survival in BRAF V600???Mutant Advanced Melanoma Treated with Vemurafenib, New England Journal of Medicine, vol.366, issue.8, pp.707-714, 1112302. ,
DOI : 10.1056/NEJMoa1112302
Co-development of a companion diagnostic for targeted cancer therapy, New Biotechnology, vol.29, issue.6, pp.682-688 ,
DOI : 10.1016/j.nbt.2012.02.002
Multisite analytic performance studies of a real-time polymerase chain reaction assay for the detection of BRAF V600E mutations in formalin-fixed, paraffin-embedded tissue specimens of malignant melanoma, Arch Pathol Lab Med, vol.2012, issue.13611, pp.1385-1391 ,
Analytical performance of a realtime PCR-based assay for V600 mutations in the BRAF gene, used as the companion diagnostic test for the novel BRAF inhibitor vemurafenib in metastatic melanoma, Diagn Mol Pathol, vol.2012, issue.211, pp.1-8 ,
Evaluation of BRAF Mutation Testing Methodologies in Formalin-Fixed, Paraffin-Embedded Cutaneous Melanomas, The Journal of Molecular Diagnostics, vol.15, issue.1, pp.70-80 ,
DOI : 10.1016/j.jmoldx.2012.08.003
Tumour molecular profiling for deciding therapy???the French initiative, Nature Reviews Clinical Oncology, vol.456, issue.8, pp.479-486 ,
DOI : 10.1038/nrclinonc.2012.42
Europe Does It Better: Molecular Testing across a National Health Care System???The French Example, American Society of Clinical Oncology Educational Book, vol.33, pp.332-339, 2013. ,
DOI : 10.1200/EdBook_AM.2013.33.332
Detection of BRAF p.V600E Mutations in Melanomas, The Journal of Molecular Diagnostics, vol.15, issue.1, pp.94-100 ,
DOI : 10.1016/j.jmoldx.2012.09.001
Les tests de génétique moléculaire pour l'accès aux therapies ciblées en 2012 Collection Bilans d'activité et d'évaluation, ouvrage collectif édité par l'INCa, Boulogne-Billancourt, décembre 2012. [INCa.Molecular genetics tests for access to targeted therapies in 2012. Collective summary of activity and evaluation, 2012. ,
Synthèse de l'activité des plateformes hospitalières de génétique moléculaire des cancers en 2011 Collection Bilan d'activité et d'évaluation, ouvrage collectif édité par l'INCa, Boulogne-Billancourt, décembre 2012. [INCa. Review of the activity of hospital platforms of cancer molecular genetics in 2011. Collective summary of activity and evaluation, 2012. ,
Intra-and inter-tumor heterogeneity of BRAF(V600E)) mutations in primary and metastatic melanoma, PLoS One, vol.7, issue.1, p.22235286 ,
Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAF mutations, BMC Cancer, vol.2014, issue.141, p.13 ,
Detection of BRAF V600 Mutations in Metastatic Melanoma, The Journal of Molecular Diagnostics, vol.15, issue.6, pp.790-795 ,
DOI : 10.1016/j.jmoldx.2013.07.003
Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study, The Lancet Oncology, vol.15, issue.3, pp.323-355, 2014. ,
DOI : 10.1016/S1470-2045(14)70012-9
Molecular Platforms Utilized to Detect BRAF V600E Mutation in Melanoma, Seminars in Cutaneous Medicine and Surgery, vol.31, issue.4, pp.267-273 ,
DOI : 10.1016/j.sder.2012.07.007
Impact of Mutation Type and Amplicon Characteristics on Genetic Diversity Measures Generated Using a High-Resolution Melting Diversity Assay, The Journal of Molecular Diagnostics, vol.15, issue.1, pp.130-137 ,
DOI : 10.1016/j.jmoldx.2012.08.008
Detection of BRAF V600E mutations in skin metastases of malignant melanoma by monoclonal antibody VE1, Journal of the American Academy of Dermatology, vol.67, issue.3, pp.488-91, 2012. ,
DOI : 10.1016/j.jaad.2012.03.022